P. David Southwell's most recent trade in Rocket Pharmaceuticals Inc was a trade of 150,000 Common Stock done . Disclosure was reported to the exchange on Aug. 3, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Rocket Pharmaceuticals Inc | Mr. David P. Southwell | Director | Other type of transaction at price $ 0.00 per share. | 03 Aug 2026 | 150,000 | 204,522 (0%) | 0% | 0 | Common Stock | |
| Rocket Pharmaceuticals Inc | Mr. David P. Southwell | Director | 18 Jun 2026 | 64,860 | 64,860 | - | - | Stock Option (Right to Buy) | ||
| Rocket Pharmaceuticals Inc | Mr. David P. Southwell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2026 | 22,862 | 54,522 (0%) | 0% | 0 | Common Stock | |
| PTC Therapeutics Inc | Mr. David P. Southwell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 4,000 | 20,850 (0%) | 0% | 0 | Common Stock | |
| PTC Therapeutics Inc | Mr. David P. Southwell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 4,000 | 20,850 (0%) | 0% | 0 | - | |
| PTC Therapeutics Inc | Mr. David P. Southwell | Director | 02 Jan 2026 | 3,475 | 3,475 | - | - | Stock Option (Right to Buy) | ||
| PTC Therapeutics Inc | Mr. David P. Southwell | Director | 09 Sep 2025 | 12,000 | 0 | - | - | Stock Option (Right to Buy) | ||
| PTC Therapeutics Inc | Mr. David P. Southwell | Director | Sale of securities on an exchange or to another person at price $ 58.34 per share. | 09 Sep 2025 | 12,000 | 16,850 (0%) | 0% | 58.3 | 700,080 | Common Stock |
| PTC Therapeutics Inc | Mr. David P. Southwell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.86 per share. | 09 Sep 2025 | 12,000 | 28,850 (0%) | 0% | 30.9 | 370,320 | Common Stock |
| PTC Therapeutics Inc | Mr. David P. Southwell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.86 per share. | 09 Sep 2025 | 12,000 | 28,850 (0%) | 0% | 30.9 | 370,320 | - |
| PTC Therapeutics Inc | Mr. David P. Southwell | Director | Sale of securities on an exchange or to another person at price $ 58.34 per share. | 09 Sep 2025 | 12,000 | 16,850 (0%) | 0% | 58.3 | 700,080 | - |
| Rocket Pharmaceuticals Inc | Mr. David P. Southwell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2025 | 30,000 | 31,660 (0%) | 0% | 0 | Common Stock | |
| PTC Therapeutics Inc | Mr. David P. Southwell | Director | 03 Jan 2025 | 8,800 | 8,800 | - | - | Stock Option (Right to Buy) | ||
| PTC Therapeutics Inc | Mr. David P. Southwell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 4,000 | 16,850 (0%) | 0% | 0 | Common Stock | |
| PTC Therapeutics Inc | Mr. David P. Southwell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 4,000 | 16,850 (0%) | 0% | 0 | - | |
| Rocket Pharmaceuticals Inc | Mr. David P. Southwell | Director | 13 Jun 2024 | 23,944 | 23,944 | - | - | Stock Option (Right to Buy) | ||
| PTC Therapeutics Inc | Mr. David P. Southwell | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 08 May 2024 | 1,650 | 12,850 (0%) | 0% | 0 | Common Stock | |
| Rocket Pharmaceuticals Inc | Mr. David P. Southwell | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 02 May 2024 | 113,124 | 1,660 (0%) | 0% | 0 | Common Stock | |
| Rocket Pharmaceuticals Inc | Mr. David P. Southwell | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 02 May 2024 | 59,716 | 113,124 (0%) | 0% | 0 | Common Stock | |
| Rocket Pharmaceuticals Inc | Mr. David P. Southwell | Director | 12 Apr 2024 | 70,000 | 29,624 | - | - | Stock Option (Right to Buy) | ||
| Rocket Pharmaceuticals Inc | Mr. David P. Southwell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.34 per share. | 12 Apr 2024 | 70,000 | 165,160 (0%) | 0% | 4.3 | 303,940 | Common Stock |
| Rocket Pharmaceuticals Inc | Mr. David P. Southwell | Director | Sale of securities on an exchange or to another person at price $ 24.22 per share. | 12 Apr 2024 | 59,716 | 105,444 (0%) | 0% | 24.2 | 1,446,560 | Common Stock |
| Rocket Pharmaceuticals Inc | Mr. David P. Southwell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.34 per share. | 12 Apr 2024 | 29,624 | 124,784 (0%) | 0% | 4.3 | 128,627 | Common Stock |
| Rocket Pharmaceuticals Inc | Mr. David P. Southwell | Director | 12 Apr 2024 | 29,624 | 0 | - | - | Stock Option (Right to Buy) | ||
| Rocket Pharmaceuticals Inc | Mr. David P. Southwell | Director | Sale of securities on an exchange or to another person at price $ 25.16 per share. | 12 Apr 2024 | 10,284 | 95,160 (0%) | 0% | 25.2 | 258,704 | Common Stock |
| Rocket Pharmaceuticals Inc | Mr. David P. Southwell | Director | Sale of securities on an exchange or to another person at price $ 24.05 per share. | 12 Apr 2024 | 10,000 | 114,784 (0%) | 0% | 24.1 | 240,520 | Common Stock |
| PTC Therapeutics Inc | Mr. David P. Southwell | Director | 15 Feb 2024 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | ||
| PTC Therapeutics Inc | Mr. David P. Southwell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 4,000 | 14,500 (0%) | 0% | 0 | Common Stock | |
| Rocket Pharmaceuticals Inc | Mr. David P. Southwell | Director | 22 Jun 2023 | 25,850 | 25,850 | - | - | Stock Option (Right to Buy) | ||
| PTC Therapeutics Inc | Mr. David P. Southwell | Director | 17 Apr 2023 | 11,429 | 0 | - | - | Stock Option (Right to Buy) | ||
| PTC Therapeutics Inc | Mr. David P. Southwell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.01 per share. | 17 Apr 2023 | 11,429 | 21,929 (0%) | 0% | 18.0 | 205,836 | Common Stock |
| PTC Therapeutics Inc | Mr. David P. Southwell | Director | Sale of securities on an exchange or to another person at price $ 50.69 per share. | 17 Apr 2023 | 6,241 | 15,688 (0%) | 0% | 50.7 | 316,348 | Common Stock |
| PTC Therapeutics Inc | Mr. David P. Southwell | Director | Sale of securities on an exchange or to another person at price $ 51.43 per share. | 17 Apr 2023 | 5,188 | 10,500 (0%) | 0% | 51.4 | 266,840 | Common Stock |
| PTC Therapeutics Inc | Mr. David P. Southwell | Director | Sale of securities on an exchange or to another person at price $ 50.05 per share. | 31 Mar 2023 | 2,571 | 10,500 (0%) | 0% | 50.0 | 128,672 | Common Stock |
| PTC Therapeutics Inc | Mr. David P. Southwell | Director | 31 Mar 2023 | 2,571 | 11,429 | - | - | Stock Option (Right to Buy) | ||
| PTC Therapeutics Inc | Mr. David P. Southwell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.01 per share. | 31 Mar 2023 | 2,571 | 13,071 (0%) | 0% | 18.0 | 46,304 | Common Stock |
| PTC Therapeutics Inc | Mr. David P. Southwell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 27.05 per share. | 27 Mar 2023 | 10,000 | 20,500 (0%) | 0% | 27.1 | 270,500 | Common Stock |
| PTC Therapeutics Inc | Mr. David P. Southwell | Director | 27 Mar 2023 | 10,000 | 0 | - | - | Stock Option (Right to Buy) | ||
| PTC Therapeutics Inc | Mr. David P. Southwell | Director | Sale of securities on an exchange or to another person at price $ 45.41 per share. | 27 Mar 2023 | 5,301 | 10,600 (0%) | 0% | 45.4 | 240,735 | Common Stock |
| PTC Therapeutics Inc | Mr. David P. Southwell | Director | Sale of securities on an exchange or to another person at price $ 44.71 per share. | 27 Mar 2023 | 4,599 | 15,901 (0%) | 0% | 44.7 | 205,618 | Common Stock |
| PTC Therapeutics Inc | Mr. David P. Southwell | Director | Sale of securities on an exchange or to another person at price $ 46.03 per share. | 27 Mar 2023 | 100 | 10,500 (0%) | 0% | 46.0 | 4,603 | Common Stock |
| Tscan Therapeutics Inc | David P. Southwell | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2023 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mr. David P. Southwell | Director | 05 Jan 2023 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | ||
| PTC Therapeutics Inc | Mr. David P. Southwell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 4,000 | 10,500 (0%) | 0% | 0 | Common Stock | |
| Tscan Therapeutics Inc | David P. Southwell | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jul 2022 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Rocket Pharmaceuticals Inc | Mr. David P. Southwell | Director | 13 Jun 2022 | 47,745 | 47,745 | - | - | Stock Option (Right to Buy) | ||
| Tscan Therapeutics Inc | David P. Southwell | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 3.62 per share. | 18 May 2022 | 15,000 | 161,569 | - | 3.6 | 54,339 | Voting Common Stock |
| Tscan Therapeutics Inc | David P. Southwell | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 3.55 per share. | 18 May 2022 | 10,000 | 171,569 | - | 3.5 | 35,482 | Voting Common Stock |
| Tscan Therapeutics Inc | David P. Southwell | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 275,000 | 275,000 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mr. David P. Southwell | Director | 07 Jan 2022 | 12,000 | 12,000 | - | - | Stock Option (Right To Buy) | ||
| PTC Therapeutics Inc | Mr. David P. Southwell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2022 | 3,200 | 6,500 (0%) | 0% | 0 | Common Stock | |
| Tscan Therapeutics Inc | David P. Southwell | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2021 | 48,670 | 21,161 | - | - | Stock Option (Right to Buy) | |
| Tscan Therapeutics Inc | David P. Southwell | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.97 per share. | 23 Dec 2021 | 48,670 | 146,569 | - | 2.0 | 95,880 | Voting Common Stock |